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In the previous issue of Critical Care, Hollmen and 
colleagues [1] investigate the utility of a novel biomarker 
of acute kidney injury (AKI) for the pre-harvest assess-
ment of likely outcomes of kidney transplantation from 
deceased donors. AKI is a syndrome that is associated 
with a major burden of morbidity and mortality in a 
variety of high risk patient populations, many of them 
cared for by intensivists. Clinical and translational 
research in recent years has focused on improvements in 
the diagnostic and prognostic evaluation of AKI to 
improve care. Validation of new systems for the diagnosis 
and staging of AKI have been important advances, and 
the discovery and validation of novel biomarkers of AKI 
that can achieve earlier diagnosis and improve prognostic 
stratiﬁ  cation have been a more recent focus in the ﬁ  eld 
[2]. One such marker is neutrophil gelatinase-associated 
lipocalin (NGAL), which is a 25-kDa gelatinase-bound 
protein that was originally characterized in neutrophils. 
In recent years, NGAL has been shown to be produced in 
the kidney following ischemic or nephrotoxic injury in 
both animals and humans, and has clinical utility for the 
early or diﬀ  erential diagnosis and prognostic evaluation 
of AKI [3-6].
Renal transplantation is a clinical setting of ischemia-
reperfusion injury that includes many features of 
laboratory experimental models of AKI, including the 
timed development of acute tubular necrosis (ATN), 
potentially permitting the use of agents for primary or 
secondary prophylaxis to prevent or ameliorate AKI. 
Delayed graft function (DGF) caused by severe ATN, 
deﬁ  ned by a requirement for dialysis during the initial 
post-transplant week, complicates postoperative manage-
ment, and if prolonged (>14 days), adversely eﬀ  ects 
allograft survival. Th   e incidence of DGF is rising with the 
growing practice of accepting expanded criteria donors 
to increase transplantation rates. Th  ere is a limited 
literature investigating the utility of NGAL for the 
diagnostic and prognostic evaluation of AKI in kidney 
transplantation. Hollmen and colleagues [7], also the 
authors of the paper commented on here, previously 
found that urine NGAL from the recipient on the ﬁ  rst 
post-transplant day was of moderate utility to predict 
DGF, particularly prolonged DGF that correlated with 
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© 2011 BioMed Central Ltdworse 1-year graft survival. Similarly, others have shown 
that a variety of biomarkers of renal tubular injury/
damage [8-12] or serum cystatin C (a marker of kidney 
function/glomerular ﬁ   ltration rate (GFR)) [11,13] can 
similarly diagnose AKI secondary to DGF in the early 
post-transplant period better than a combination of the 
usual clinical parameters of kidney function (serial 
monitoring of serum creatinine and urine output) with 
known DGF risk factors (ischemia times, and so on).
Hollmen and colleagues [1] demonstrate that donor 
urine NGAL (but not serum NGAL) is similarly useful to 
help with the pre-harvest prediction of DGF after renal 
transplantation from deceased donors. Speciﬁ  cally, they 
studied pre-harvest serum and urine NGAL levels in 99 
consecutive, deceased donors, and followed the clinical 
courses of their 176 kidney recipients. No other AKI 
biomarkers were measured. Th  ey found that high pre-
harvest urine NGAL levels were more common in those 
who developed prolonged DGF. In receiver operating 
characteristic (ROC) curve analysis, donor urine NGAL 
had poor utility for prediction of DGF (area under the 
curve 0.595) or prolonged DGF (area under the curve 
0.616). However, increased donor urine NGAL was a 
signiﬁ  cant risk factor for prolonged DGF independent of 
other important predictors (expanded criteria donor 
status and estimated GFR). Th  ese ﬁ   ndings have clear 
implications with regard to potentially improved assess-
ment of deceased donor suitability for potential renal 
allograft donation. Further  more, their ﬁ  ndings augment 
the growing evidence-base suggesting the utility of 
biomarkers of kidney damage to provide additional 
diagnostic and prognostic information regarding the 
presence, severity, and likely course of AKI in high-risk 
settings, beyond what can be discerned by the use of 
markers of renal function (GFR and urine output) alone. 
Such diagnostic and prognostic accuracy has the 
potential to signiﬁ  cantly improve the clinical evaluation 
and management of AKI, including aggressive resusci-
tation of patients with AKI but no evidence of kidney 
damage (‘prerenal’, reversible renal hypoperfusion result-
ing in decreased GFR) [4,6], and early initiation of dialysis 
in patients with evolving AKI caused by severe ATN 
(based upon biomarker evidence of severe renal tubular 
damage) [3,4,14]. Th  us, the emerging use of novel AKI 
biomarkers of renal dysfunction and damage can oﬀ  er 
the prospect of appropriate, early, goal-directed therapy 
of AKI in high risk patients, including prompt reversal 
where possible [6], and aggressive renal support where 
necessary [3,4,14].
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